The clinical effect of DEP of total hip arthroplasty

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-17011485

Enrollment

Unknown

Registered

2017-05-25

Start date

2016-03-01

Completion date

Unknown

Last updated

2017-06-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hip osteoarthritis

Interventions

A:TXA+DEP

B:TXA

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Aged 18 years and older and scheduled primary unilateral total hip arthroplasty for OA or osteonecrosis of femoral head (ONFH) at our hospital

Exclusion criteria

Exclusion criteria: revision surgery, bilateral joint arthroplasty, and known allergy to TXA and DEP. Considering the risk of thrombosis caused by the antifibrinolytic effect of TXA, the patient who had suffered cardiovascular disease (history of myocardial infraction, angina, and atrial fibrillation), cerebrovascular pathology (previous history of stroke), clotting disorders, thromboembolic disorders (history of history of deep vein thrombosis (DVT) or pulmonary embolism (PE)) was also excluded.

Design outcomes

Primary

Measure	Time frame
haemoglobin level;Blood loss;Hct;Transfusion;ESR, CRP, IL-6;hip function evaluation ;perioperative complications: deep vein thrombosis ;cost;sweeling;nausea and vomiting;drainage;length of hospital stay;	—

Countries

China

Contacts

Public ContactZhou Zongke

West China Hospital, Sichuan University

zongke@126.com+86 18980601028

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026